Seeking Alpha·Jun 16, 2026
Dogwood Therapeutics, Inc. (DWTX) Shareholder/Analyst Call Prepared Remarks TranscriptDogwood Therapeutics, Inc. (DWTX) Shareholder/Analyst Call Prepared Remarks Transcript
Dogwood Therapeutics, Inc.(DWTX)Earnings, Financials & Key Ratios
DWTX•NASDAQ
$1.38
Price updated Jul 6, 2026
AboutDogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It also develops IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Virios Therapeutics, Inc. and changed its name to Dogwood Therapeutics, Inc. in October 2024. The company was founded in 2012 and is headquartered in Alpharetta, Georgia.Show more
- Revenue$0
- EBITDA-$28M-128.9%
- Net Income-$34M-177.4%
- EPS (Diluted)-4.32+65.5%
- ROE-49.23%-35.7%
DWTX Price & Volume
Dogwood Therapeutics, Inc. (DWTX) stock price & volume — 10-year historical chart
Loading chart...
Clinical Development Costs Threaten DWTX Liquidity Position
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Imminent liquidity exhaustion
Key Thesis Takeaways
- Dogwood Therapeutics faces a high-stakes transition toward its IMC-2 program for long COVID, yet the firm remains entirely pre-revenue with operating losses reaching $15.8 million in 2025Q3.
- The company's reliance on external capital to fund R&D, which peaked at $14.5 million in the same quarter, creates a significant dilution overhang for shareholders.
- Investors should monitor the precarious $6.5 million cash balance as of 2025Q4, which appears insufficient to sustain late-stage clinical trials without further value-destructive financing.
Verdict Logic
the company's precarious liquidity buffer of only $6.5 million as of 2025Q4, combined with a history of significant net losses, suggests an imminent risk of dilutive capital raises.
DWTX Growth Metrics
Dogwood Therapeutics, Inc. (DWTX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-28.82%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM39.6%
Return on Capital
10 Years-68.02%
5 Years-67.64%
3 Years-51.66%
Last Year-31.38%
DWTX Recent Earnings
Dogwood Therapeutics, Inc. (DWTX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 6/12 qtrs (50%)
Q2 2026Latest
May 14, 2026Metric
Actual
Est
EPS
$0.15+31.8%
$0.22
Rev
—
—
Q2 2026
Mar 18, 2026Metric
Actual
Est
EPS
$0.26+69.8%
$0.86
Rev
—
—
Q4 2025
Nov 6, 2025Metric
Actual
Est
EPS
$8.20-566.7%
$1.23
Rev
—
—
Q3 2025
Aug 13, 2025Metric
Actual
Est
EPS
$1.99-57.9%
$1.26
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 14, 2026 | $0.15vs $0.22+31.8% | — |
| Q2 2026 | Mar 18, 2026 | $0.26vs $0.86+69.8% | — |
| Q4 2025 | Nov 6, 2025 | $8.20vs $1.23-566.7% | — |
| Q3 2025 | Aug 13, 2025 | $1.99vs $1.26-57.9% | — |
Based on last 12 quarters of dataView full earnings history →
Latest DWTX News
Recent stock market news and headlines for Dogwood Therapeutics, Inc. (DWTX)
Peers Comparison
Key metrics vs top competitors for Dogwood Therapeutics, Inc. (DWTX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1.38 | $46.29M | -0.32 | — | — | -49.23% | — | |
| $11.09 | $1.53B | -1.08 | -2.75% | -43.5% | -50.65% | — | |
| $73.15 | $1.43B | -7.52 | -43.89% | -284.18% | -87% | — | |
| $25.59 | $1.01B | 159.94 | 3.63% | 1.27% | 1.31% | — | |
| $231.43 | $11.15B | -79.53 | -0.85% | -4.59% | -5.66% | — | |
| $205.97 | $34.95B | 26.27 | 5.87% | 8.33% | 22.11% | — |
Compare DWTX vs Peers
Dogwood Therapeutics, Inc. (DWTX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
DWTX SEC Filings & Documents
Dogwood Therapeutics, Inc. (DWTX) SEC filings — annual & quarterly reports (10-K, 10-Q)
8-K Announcements
5Material company update
Nov 6, 2025·SEC
Material company update
Oct 9, 2025·SEC
Material company update
Sep 29, 2025·SEC
10-Q Quarterly Reports
2Get notified when DWTX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
DWTX Frequently Asked Questions
Dogwood Therapeutics, Inc. (DWTX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is DWTX profitable?
Dogwood Therapeutics, Inc. (DWTX) reported a net loss of $28.3M for fiscal year 2025.
Dividend & Returns
What is DWTX's return on equity?
Dogwood Therapeutics, Inc. (DWTX) has a return on equity (ROE) of -49.2%. Negative ROE indicates the company is unprofitable.
What is Dogwood Therapeutics, Inc.'s free cash flow?
Dogwood Therapeutics, Inc. (DWTX) had negative free cash flow of $15.5M in fiscal year 2025, likely due to heavy capital investments.